Amarin: Vascepa showed reductions in reduced triglyceride levels
Amarin announced two EPA-related data presentations unveiled this week at the American Diabetes Association 77th Scientific Sessions in San Diego, CA. A post-hoc analysis of the ANCHOR study further characterizing the efficacy and safety of prescription pure EPA Vascepa in the subgroup of statin-treated women with persistent high triglycerides and diabetes mellitus type 2, showed that, compared with placebo, Vascepa reduced triglyceride levels and several other potentially atherogenic lipid parameters and inflammatory markers, and significantly increased blood EPA levels. The study titled, "Icosapent Ethyl in Statin-Treated Women with Persistent High Triglycerides and Diabetes Mellitus: ANCHOR Study Subanalysis," was led by Eliot A. Brinton, MD, FAHA, FNLA. An in vitro mechanistic study suggesting that EPA may be a potential strategy for reducing blood vessel cell dysfunction is summarized in a published presentation, "Eicosapentaenoic Acid Reduces Small Dense Low-Density Lipoprotein Oxidation and Human Endothelial Dysfunction in Vitro in a Manner Distinct from Docosahexaenoic Acid," by R. Preston Mason, PhD. The data demonstrated that EPA has antioxidant properties, distinct from DHA, that preserves certain cellular functions within blood vessel cells under disease-like conditions.